Moderna’s Covid Boom Is Ending. Why the Outlook Isn’t All Grim.

  • Order Reprints
  • Print Article

Last week was a bad one for Moderna shareholders.

The biotech company’s shares tumbled 6.7% on Thursday, and another 5.6% on Friday, after its earnings report gave investors a glimpse into how it expects its post-pandemic financials to look.